ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: miR-152-3p promotes CML development by inhibiting p27 (42), miR-342-5p inhibits proliferation caused by BCR-ABL and resistance to imatinib by targeting CCND1 (16), and miR-584 has been reported to have a possible role as a tumor suppressor in lung cancer (43).